VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | KRd in primary PCL: positive results from EMN12/HOVON129

Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses the results of the first interim analysis of the phase II EMN12/HOVON129 study (NTR5350), evaluating carfilzomib, lenalidomide and dexamethasone (KRd) in primary plasma cell leukemia (pPCL). Results from the first planned interim analysis for patients with previously untreated pPCL show that KRd provides efficient and rapid disease control, which is essential to prevent early mortality and to improve the survival of patients with this aggressive plasma cell proliferative disorder. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter